A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Clinical trial NCT06825858 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06825858
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-07
- Primary completion
- 2027-01-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.